ALPHA COGNITION INC. NEW

Zunveyl nearly eliminates the onerous GI and sleep disturbance side effects of gold-standard AChEI drugs used to treat Alzheimer's. With failure of anti-amyloid antibodies and no clear disease-modifying therapies in late-stage development (yet), the $5.5 billion Alzheimer's market is severely underserved and dissatisfied. Lean, experienced commercial team launched Zunveyl in March into the long-term care (LTC) market vertical, which accounts for 32% of Alzheimer's scripts.» Mehr auf seekingalpha.com

Dallas, Texas--(Newsfile Corp. - May 19, 2025) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition began 2025 by launching ZUNVEYL(R) (benzgalantamine) to the U.S. long-term care (LTC) market on March 17, 2025, delivering on its commercialization timeline and budget.» Mehr auf newsfilecorp.com

Alpha Cognition Inc. (NASDAQ:ACOG ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Henry Du - Interim CFO Michael McFadden - CEO Lauren D'Angelo - COO Conference Call Participants Ram Selvaraju - H.C. Wainwright Michael Freeman - Raymond James Dave Storms - Stonegate Operator Greetings and welcome to the Alpha Cognition earnings call.» Mehr auf seekingalpha.com